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Abstract
AIM: To investigate activity, toxicity, and prognostic 
factors for survival of erlotinib and fixed dose-rate gem-
citabine (FDR-Gem) in advanced pancreatic cancer.
METHODS: We designed a single-arm prospective, 
multicentre, open-label phase Ⅱ study to evaluate 
the combination of erlotinib (100 mg/d, orally) and 
weekly FDR-Gem (1000 mg/m2, infused at 10 mg/m2 
per minute) in a population of previously untreated pa-
tients with locally advanced, inoperable, or metastatic 
pancreatic cancer. Primary endpoint was the rate of 
progression-free survival at 6 mo (PFS-6); secondary 
endpoints were overall response rate (ORR), response 
duration, tolerability, overall survival (OS), and clinical 
benefit. Treatment was not considered to be of further 
interest if the PFS-6 was < 20% (p0 = 20%), while 
a PFS-6 > 40% would be of considerable interest (p1 
= 40%); with a 5% rejection error (α  = 5%) and a 
power of 80%, 35 fully evaluable patients with meta-
static disease were required to be enrolled in order to 
complete the study. Analysis of prognostic factors for 
survival was also carried out.
RESULTS: From May 2007 to September 2009, 46 pa-
tients were enrolled (male/female: 25/21; median age: 
64 years; median baseline carbohydrate antigen 19-9 
(CA 19-9): 897 U/mL; locally advanced/metastatic 
disease: 5/41). PFS-6 and median PFS were 30.4% 
and 14 wk (95%CI: 10-19), respectively; 1-year and 
median OS were 20.2% and 26 wk (95%CI: 8-43). 
Five patients achieved an objective response (ORR: 
10.9%, 95%CI: 1.9-19.9); disease control rate was 
56.5% (95%CI: 42.2-70.8); clinical benefit rate was 
43.5% (95%CI: 29.1-57.8). CA 19-9 serum levels were 
decreased by > 25% as compared to baseline in 14/23 
evaluable patients (63.6%). Treatment was well-toler-
ated, with skin rash being the most powerful predictor 
of both longer PFS (P  < 0.0001) and OS (P  = 0.01) at 
multivariate analysis (median OS for patients with or 
without rash: 42 wk vs  15 wk, respectively, Log-rank P  
= 0.03). Additional predictors of better outcome were: 
CA 19-9 reduction, female sex (for PFS), and good 
performance status (for OS). 
CONCLUSION: Primary study endpoint was not met. 
However, skin rash strongly predicted erlotinib efficacy, 
suggesting that a pharmacodynamic-based strategy for 
patient selection deserves further investigation. 
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Core tip: The most important finding reported in this 
study is the strong predictive value of the appearance 
of skin rash, related to epidermal growth factor recep-
tor (EGFR)-pathway inhibition. Our data suggest that 
patients developing any grade of skin rash during the 
treatment, can achieve disease control and survival 
comparable to those obtained with more intensive and 
more toxic chemotherapy. These findings underline 
the relevance of further investigation of the biologi-
cal mechanisms related to the occurrence of skin rash 
upon EGFR blockade in order to identify clinical/mo-
lecular biomarkers predicting toxicity and efficacy and 
to prospectively select a subset of patients who could 
potentially benefit from Gem/erlotinib.
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INTRODUCTION
Pancreatic adenocarcinoma (PDAC) is arguably the most 
aggressive solid malignancy, with nearly as many deaths 
as the number of  newly diagnosed cases each year. In 
2012 an estimated 43920 new cases and an estimated 
37390 deaths are expected to occur, making pancreatic 
carcinoma the fourth leading cause of  cancer-related 
death in the United States. The prognosis of  pancreatic 
cancer is extremely poor due to difficulties in early de-
tection and early metastatic dissemination, with a 5-year 
survival rate of  only 6%[1].
The majority of  PDAC patients present with meta-
static or inoperable disease. In this setting, systemic 
chemotherapy remains the treatment of  choice, with a 
palliative objective and a disappointing, marginal, sur-
vival advantage. Single-agent gemcitabine (Gem), admin-
istered as weekly 30-min iv infusions, has become the 
standard care for advanced PDAC based on a small but 
statistically significant advantage over bolus 5-fluoro-
uracil (5-FU), in terms of  both clinical benefit (CB) and 
survival[2]. 
Until recently, efforts to improve on single-agent 
Gem efficacy[3], by combining Gem with either a second 
cytotoxic drug or a molecularly targeted agent, have 
failed[4,5]. The addition of  erlotinib, an oral epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibi-
tor, to Gem has produced a minimal, albeit statistically 
significant, improvement in overall survival (OS), leading 
to FDA approval of  the Gem/erlotinib combination 
in the setting of  advanced, inoperable PDAC[6]. On the 
other hand, pharmacokinetic Gem modulation, achieved 
by prolonging its infusion time, is justified by the obser-
vation that deoxycytidine kinase, the enzyme converting 
Gem into its active triphosphate metabolite, is rapidly 
saturated at plasma concentrations achieved with the 
standard 30-min infusion. Consequently, the infusion 
of  Gem over a prolonged period at the constant dose 
rate of  10 mg/m2 per min (FDR-Gem) avoids enzyme 
saturation and permits greater intracellular accumula-
tion, possibly increasing Gem antitumor activity. This 
strategy has proven promising in a randomized phase Ⅱ 
trial, in which FDR-Gem significantly improved time to 
treatment failure as compared with the standard 30-min 
infusion[7]. Although formally negative, a phase Ⅲ trial 
comparing standard Gem with either FDR-Gem or the 
GEMOX combination, produced a clear signal in favor 
of  FDR-Gem, which was as effective as the GEMOX 
combination[8].
Recently, a four-drug combination including 5-FU, 
folinic acid, oxaliplatin and irinotecan (FOLFIRINOX 
regimen) has demonstrated to improve objective re-
sponse rate (ORR), progression-free survival (PFS) and 
OS over single-agent Gem administered by standard 
30-min infusion in metastatic PDAC patients[9]. How-
ever, such improved efficacy comes at the price of  sig-
nificantly higher toxicity (both hematological and non-
hematological), which restricts the use of  such regimen 
to accurately selected, young and fit patients. 
Based on our previous experience with a modified 
FDR-Gem regimen, which utilizes a lower Gem dose 
(1000 mg/m2) as compared with the original FDR-Gem 
described by Tempero et al[7] (1500 mg/m2) resulting in 
reduced hematological toxicity[10,11], we prospectively 
investigated the activity and tolerability of  FDR-Gem 
in combination with erlotinib in advanced, inoperable 
PDAC patients. 
MATERIALS AND METHODS
Patient population
Patients with cytologically or histologically proven, 
treatment-naïve, unresectable or metastatic PDAC and 
measurable disease were eligible for the study. Prior 
radiation for the management of  local disease was al-
lowed, provided that disease progression had been docu-
mented, all toxicities had resolved and treatment was 
completed at least 4 wk before study enrollment. Prior 
chemotherapy was not permitted, except for fluorouracil 
or Gem given concurrently with RT for radiosensitiza-
tion purposes. Other inclusion criteria included: age > 
18 years; Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) ≤ 3; life expectancy > 12 wk; 
adequate hematological, renal, hepatic function; absence 
of  other relevant medical conditions, potentially preclud-
ing the delivery of  the planned treatment. The study was 
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reviewed and approved by the institutional review board 
of  the Regina Elena National Cancer Institute (Rome, 
Italy), and written informed consent, according to In-
stitutional requirements, was obtained from all patients 
before entering the study.
Treatment and study design
This was a single-arm, open-label, multicenter phase Ⅱ 
study, evaluating the activity and tolerability of  the com-
bination of  FDR-Gem and erlotinib in patients with ad-
vanced PDAC. Study patients received Gem at the dose 
of  1000 mg/m2, administered as a 10 mg/m2 per min 
FDR iv infusion (100 min total infusion time)[10,11], weekly 
for 7 consecutive weeks and on days 1, 8, and 15 of  a 4-wk 
cycle thereafter for a maximum of  6 cycles in the absence 
of  progressive disease (PD) or unacceptable toxicity; er-
lotinib was administered as a daily oral dose of  100 mg 
from day 1 until PD or unacceptable toxicity. Toxicities 
were recorded according to the National Cancer Insti-
tute-Common Toxicity Criteria Version 3.0. Appropriate 
dose reductions of  each study agent were planned in case 
of  severe toxicities. Tumor assessments were performed 
at the end of  cycle 1 and every 2 cycles thereafter. 
Response and progression were evaluated using the 
Response Evaluation Criteria in Solid Tumours (RECIST 
1.0)[12]. All patients who had measurable lesions and who 
had at least one objective tumour assessment after base-
line were considered evaluable for response. The com-
posite end point of  CB was evaluated according to the 
criteria established by Burris et al[2] and included the as-
sessment of  pain (pain intensity and analgesic consump-
tion) and functional impairment (assessed by Karnofsky 
PS) as primary measures and weight change (assessed by 
body weight) as a secondary measure. Each patient was 
classified as positive, stable, or negative for each of  the 
primary CB measures (pain intensity or PS)[2]. For all pa-
tients, positive indicated a sustained (≥ 4 wk) improve-
ment over baseline. If  the patient was stable on both pri-
mary measures of  clinical benefit, the patient was then 
classified as either positive or non-positive on the basis 
of  the secondary clinical benefit measure of  weight. For 
patients to achieve an overall rating of  a positive CB, 
they had to be positive for at least one parameter with-
out being negative for any of  the others. 
Statistical analysis
PFS rate at 6 mo (PFS-6) was selected as the primary 
study endpoint. Secondary endpoints were ORR, re-
sponse duration, tolerability, OS, and CB. Sample size 
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Figure 1  Kaplan-Meier analysis of progression-free survival and overall 
survival in the intent to treat population. A: Progression-free survival (PFS); 
B: Overall survival (OS).
Table 1  Patients’ characteristics  n  (%)
Characteristics Categories Data
Age (yr) Median (range)      64 (35-81)
Gender Male 25 (54)
Female 21 (46)
Stage Locally advanced   5 (11)
Metastatic 41 (89)
ECOG PS 0 10 (22)
1 26 (56)
2   9 (20)
3 1 (2)
Basal CA 19-9 (U/mL) Median (range)          897 (1-49, 483)
Interval between symptoms and 
treatment (wk)
Median (range)      12 (2-179)
Clinical benefit Evaluable 33 (75)
Not evaluable 13 (25)
Follow-up (wk) Median (range) 21.5 (2-91)
Number of administrations Median (range)      9 (1-29)
PS: Performance status; ECOG: Eastern Cooperative Oncology Group; CA 
19-9: Carbohydrate antigen 19-9.
Parameter Patients (n  = 46)
CR/PR   5 (10.9)
SD 21 (45.7)
PD 20 (43.4)
CB
   Pos 15 (42.9)
   Neg 20 (57.1)
CA 19-9 reduction > 25%  14 (63.6)1
1In 23 evaluable patients. CR: Complete response; PR: Partial response; SD: 
Stable disease; PD: Progressive disease; CB: Clinical benefit; Pos: Positive; 
Neg: Negative; CA 19-9: Carbohydrate antigen 19-9.
Table 2  Objective response, clinical benefit response and car-
bohydrate antigen 19-9 reduction in the overall population 
n  (%)
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was computed according to the exact single-stage Phase 
II design described by A’Hern[13]. The treatment was not 
considered to be of  further interest if  the PFS rate at 
6 mo was < 20% (p0 = 20%). The alternate hypothesis 
assumed that a PFS rate at 6 mo of  > 40% would be 
of  considerable interest (p1 = 40%). With a 5% rejec-
tion error (α = 5%) and a power of  80%, a total of  35 
fully evaluable patients were needed to complete the 
study. In order to have enough power to also analyze the 
‘pure’ metastatic sub-population separately, 46 patients 
were planned to enter the study, taking into account a 
dropout rate of  approximately 15%. The Kaplan-Meier 
method was used to estimate PFS and OS[14]. PFS was 
defined as the time from the first day of  treatment to 
the first observation of  disease progression or death 
due to any cause and OS was defined as the time from 
the first day of  treatment to death from any cause. ORR 
was estimated as the proportion of  patients evaluable 
for response who met RECIST criteria for complete or 
partial response (CR or PR). Response duration was cal-
culated for all patients achieving a PR or CR as the time 
from first objective status assessment of  CR/PR to the 
first time documented PD or death. Cox proportional 
hazards models were used to compare survival among 
different patient/disease characteristics and treatment 
response groups[15]; hazard ratios were appropriately de-
rived from these models. The SPSS statistical software 
package version 20.0 (SPSS, Inc, Chicago, IL, United 
States) was used for all statistical analyses.
RESULTS
Between May 2007 and September 2009, 46 patients 
with advanced-stage PDAC were enrolled in the study 
from 3 institutions. Patient characteristics are shown in 
Table 1. 
Treatment outcome
All 46 patients were evaluable for response according to 
RECIST criteria. PR and stable disease (SD) were ob-
served in 5/46 (10.9%) and 21/46 (45.7%) patients, re-
spectively, for an overall disease control rate (DCR), de-
fined as the percentage of  patients who had CR, PR or 
SD as their best response, of  56.5% (95%CI: 42.2-70.8); 
PD was documented at the first response assessment in 
20 patients (43.5%). Median response duration was 27.4 
wk (range 11-45 wk); median duration of  stable disease 
was 27.6 wk (range 10-85 wk). Fifteen out of  35 evalu-
able patients (42.9%) experienced a positive CB. CA 
19-9 serum levels were decreased by > 25% as compared 
to baseline in 14/23 evaluable patients (63.6%). Similar 
results were obtained in the pure metastatic population 
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Table 4  Multivariate analysis for progression-free survival and 
overall survival 
Variables       PFS
   HR (95%CI)    P  value
                 OS
 HR (95%CI)   P  value
PS NA 8.78 (1.60-48.2) 0.01
Gender   2.99 (1.13-7.90) 0.03 2.66 (0.85-8.35) 0.09
CB NA 3.07 (0.87-10.8) 0.08
Skin rash1     8.66 (2.65-28.32) < 0.0001 5.10 (1.41-18.4) 0.01
CA 19-9 decrease2   2.64 (0.93-7.45) 0.07 3.36 (1.05-10.6) 0.04
 
Table 3  Toxicity (maximum toxicity per patient)  n  (%)
Variables Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
Haemoglobin 15 (32.6) 17 (37.0) 10 (21.7) 4 (8.7) -
Leucopenia 29 (63.0) 3 (6.5)   9 (19.6)   5 (10.9) -
Neutropenia 25 (54.3) 2 (4.3)   9 (19.6)   8 (17.4) 2 (4.3)
Febrile neutropenia 44 (95.7) - 2 (4.3) - -
Platelet 32 (69.6)   6 (13.0) 2 (4.3)   6 (13.0) -
Fever 35 (76.1)   9 (19.6) 2 (4.3) - -
Bleeding 45 (97.8) - - 1 (2.2) -
Alopecia 41 (89.1) 4 (8.7) 1 (2.2) - -
Anorexia 38 (82.6)   7 (15.2) 1 (2.2) - -
Asthenia 22 (47.8)  12 (26.1) 11 (23.9) 1 (2.2) -
Cardiac 45 (97.8) - 1 (2.2) - -
Skin 24 (52.2)   15 (32.6)   5 (10.9) 2 (4.3) -
Diarrhoea 18 (39.1)   16 (34.8) 11 (23.9) 1 (2.2) -
Constipation   46 (100.0) - - - -
Stomatitis 42 (91.3) 1 (2.2) 3 (6.5) - -
ALT 24 (52.2) 13 (28.3)   6 (13.0) 3 (6.5) -
AST 19 (41.3) 12 (26.1) 10 (21.7) 4 (8.7) 1 (2.2)
Bilirubine 42 (91.3) 2 (4.3) 2 (4.3) - -
Renal 43 (93.5) 3 (6.5) - - -
Neurological 45 (97.8) 1 (2.2) - - -
Nausea 39 (84.8) 3 (6.5) 4 (8.7) - -
Vomiting 40 (87.0) 3 (6.5) 3 (6.5) - -
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.
1None vs any grade; 2Carbohydrate antigen 19-9 (CA 19-9) decrease of ≥
25%. PFS: Progression-free survival; OS: Overall survival; PS: Performance 
status according to Eastern Cooperative Oncology Group (PS 0-1 vs PS 2-3); 
CB: Clinical benefit; NA: Not applicable.
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(data not shown). At a median follow-up of  23.6 wk 
(range 2-139 wk), the median PFS and 1-year PFS rate 
were 14 wk (95%CI: 10-19) and 10.9%, respectively; 
PFS-6 (primary study endpoint) was 30.4% (Figure 1A). 
The median OS and 1-year OS rate were 26 wk (95%CI: 
8-43 wk) and 20.2%, respectively (Figure 1B). In the 
pure metastatic population the corresponding figures 
were: median PFS: 14 wk, PFS-6: 24.4 %, median OS: 20 
wk, 1-year OS: 12.7% (Table 2, data not shown).
Toxicity
All patients were evaluable for toxicity. Main hemato-
logical and non-hematological toxicities are summarized 
in Table 3. Treatment protocol was well tolerated, with 
only 3 serious adverse events that required hospital-
ization: 2 episodes of  GI bleeding and 1 duodenal 
perforation. Three patients (7%) reported grade 4 
toxicities (neutropenia in 2 patients and asymptomatic 
transaminase elevation in 1 patient). Grade 3 hemato-
logical toxicity was also rare: anemia in 4 patients (9%), 
neutropenia in 8 patients (18%), thrombocytopenia in 
5 patients (11%); only 1 patient (2%) experienced fe-
brile neutropenia. The main non-hematological toxicity 
were: asymptomatic serum transaminase elevation and 
hyperbilirubinemia (grade 3 in 9% of  patients); grade 3 
diarrhea in 1 patient (2%); grade 2 and 3, erlotinib-re-
lated skin rash in 11% and 4% of  patients, respectively. 
Median time to rash was 7 d. Gem and erlotinib doses 
were reduced in 14 and 3 patients, respectively. No toxic 
deaths were recorded.
Clinical predictors of response and survival
A positive CB and skin rash (any grade) were significant, 
independent predictors of  DCR at multivariate analy-
sis, in both the overall and pure metastatic populations. 
Female gender (P = 0.03) and skin rash (any grade, P 
< 0.0001) were significant, independent predictors of  
longer PFS (Table 4). ECOG PS (0-1, P = 0.01), skin 
rash (any grade, P = 0.03), and carbohydrate antigen (CA 
19-9) decrease (> 25% relative to baseline, P = 0.04) 
were significantly associated with longer OS at multi-
variate analysis (Table 4). Conversely, the occurrence 
of  other Gem- or erlotinib-related toxicities, such as 
hematological toxicity and diarrhea, did not significantly 
impact on survival outcomes. The impact of  these fac-
tors on PFS and OS was further confirmed by Kaplan-
Meier analysis (Figures 2 and 3): in particular, median 
PFS and median OS were both significantly longer in 
patients experiencing any grade of  skin rash (21 wk vs 10 
wk, Log-rank P = 0.001, and 42 wk vs 15 wk, Log-rank P 
= 0.03, respectively) (Figures 2A and 3A). In the “pure 
metastatic” population, gender and skin rash (P = 0.007 
and P = 0.002), and gender, PS, CB and skin rash (P = 
0.01, P = 0.06, P = 0.02 and P = 0.02) were significant, 
independent predictors of  PFS and OS, respectively, at 
multivariate analysis (data not shown).
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Figure 2  Kaplan-Meier analysis of independent progression-free survival predictors. A: Progression-free survival (PFS) by sex; B: PFS by skin rash; C: PFS by 
carbohydrate antigen 19-9 decrease. 
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Figure 3  Kaplan-Meier analysis of independent overall survival predictors. A: Overall survival (OS) by sex; B: OS by skin rash; C: OS by carbohydrate antigen 
19-9 decrease; D: OS by Eastern Cooperative Oncology Group performance status (PS); E: OS by clinical benefit. Pos: Positive; Neg: Negative.
DISCUSSION
In this study, performed in an unselected patient popula-
tion, the administration of  FDR-Gem in combination 
with erlotinib proved to be feasible, well tolerated, and 
moderately active. However, the planned goal to obtain 
a PFS-6 > 40% was not reached (PFS-6: 31.8%). Thus, 
the addition of  erlotinib to an FDR-Gem backbone in 
unselected patients is unlikely to improve on historical 
result; indeed 1-year OS (21.6%), median OS (26 wk, 
95%CI: 9-43), and activity in terms of  responses, with a 
DCR of  59% are within the ranges reported with single-
agent Gem, administered either as a 30-min iv infusion 
or as FDR, or with the combination of  Gem and erlo-
tinib[2,6-8,10].
The safety profile of  the tested FDR-Gem/erlotinib 
combination is extremely manageable, an important issue 
in advanced PDAC patients, who are often frail and at a 
high risk of  an adverse impact of  treatment on quality 
of  life. In particular, we confirm here that administering 
FDR-Gem at 1000 mg/m2, as in previous experiences 
from our group[10,11], decreases hematological toxicity in 
comparison with the original FDR-Gem schedule devel-
oped by Tempero et al[7], where FDR-Gem was adminis-
tered at the 1500 mg/m2 dose level (grade 3-4 neutrope-
nia 23% in the present trial vs 48.8% in Tempero’s trial). 
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was also an independent prognostic factor for survival, 
thus adding to the numerous evidence supporting the 
prognostic role (and clinical utility) of  a CA 19-9 reduc-
tion, regardless of  the chosen cut-off  point[28-31]. 
In conclusion, although the study reported herein 
failed to meet its primary endpoint of  prolonging PFS 
with the addition of  erlotinib to FDR-Gem, intriguing 
data on skin rash do suggest that a subset of  advanced 
PDAC patients could actually achieve disease control 
and survival comparable to those obtained with more in-
tensive (and more toxic) polychemotherapy approaches, 
such as FOLFIRINOX and Gem/nab-paclitaxel com-
binations, with a well tolerated and easily manageable 
regimen, potentially also suitable for elderly and unfit 
patients. However, in order for this strategy to become a 
concrete treatment option, an in-depth investigation of  
the biological mechanisms underlying the occurrence of  
skin rash upon EGFR blockade is required to identify 
clinical/molecular biomarkers predicting toxicity and 
efficacy and to prospectively select patients who could 
potentially benefit from Gem/erlotinib combinations. 
COMMENTS
Background
Pancreatic adenocarcinoma has a dismal prognosis. Although the disappointing 
survival advantage obtained in many studies, chemotherapy is the only treat-
ment option for the majority of patients, and single agent gemcitabine (Gem) 
remains standard care for many of them. Recently, the polychemotherapy regi-
men named FOLFIRINOX has produced an improvement in survival over single 
agent Gem but require an accurate selection of young and fit patients to limit 
treatment-related toxicities. In order to improve Gem efficacy, pharmacokinetic 
Gem modulation and combination with other chemotherapeutic agent has been 
proposed. To this regard, the prolonged infusion at constant dose rate has 
shown promising results in phase Ⅱ and Ⅲ trials and the addition of erlotinib 
to Gem has provided a minimal, albeit statistically significant, improvement in 
survival. 
Research frontiers
In the field of advanced pancreatic adenocarcinoma (PDAC), the research 
hotspot is to find active regimen, for patients not suitable for aggressive combi-
nation chemotherapy, able to improve survival over single agent Gem, without 
worsening tolerability. In the context of targeted therapies, applied to PDAC, but 
also any other malignancy, the opportunity of prospectively select patients who 
could benefit from targeted therapy plays a fundamental role.
Innovations and breakthroughs
The combination of fixed dose-rate (FDR)-Gem at 1000 mg/m2 and erlotinib 
appears feasible, well tolerated and extremely manageable. In comparison 
to other FDR-Gem schedules with different doses (1500 or 1200 mg/m2), the 
regimen shows a reduced hematological toxicity profile. This suggests that the 
schedule is a feasible platform for combining targeted therapies. In the study, a 
strong predictive value of the appearance of skin rash is demonstrated. Patients 
developing erlotinib-related skin toxicity experienced a more than doubled me-
dian overall survival, comparable to that obtained with more intensive polyche-
motherapy approaches. This relation has not been reported for other toxicities 
(hematologic toxicities or diarrhea). Moreover, occurrence of clinical benefit and 
reduction in carbohydrate antigen levels > 25% from baseline also proved to be 
an independent prognostic factor for survival. All these data confirm these fac-
tors as an important guide for the management of advanced PDAC patients. 
Applications 
The study results suggest the importance of investigating the biological mecha-
nisms underlying the occurrence of skin rash upon epidermal growth factor 
receptor blockade. The identification of clinical/molecular biomarkers is strongly 
required to predict toxicity and efficacy and to prospectively select patients who 
Other experiences with a different EGFR-TKI (gefitinib) 
have also confirmed an extremely safe and manage-
able toxicity profile of  Gem-FDR at a lower dose (1200 
mg/m2), thus suggesting these combinations as feasible 
platforms for associations with additional chemothera-
peutics or different targeted agents[16].  
Though the combination under study proved feasible 
and well tolerated, the question remains as to whether 
such a strategy (i.e., adding an EGFR kinase inhibitor to 
a FDR-Gem backbone in unselected patients) is worthy 
pursuing if  it does not improve efficacy. As the results 
of  the trial are technically negative (primary endpoint 
was not met), the easiest answer would be that this 
combination does not merit further investigation, par-
ticularly in a scenario, such as that of  advanced PDAC 
treatment, where novel polychemotherapy strategies 
(FOLFIRINOX and Gem/nab-paclitaxel combinations) 
are moving the field forward and, for the first time in 
almost 20 years, show increased efficacy and improved 
survival as compared with single-agent Gem. However, 
survival analysis of  the present trial and of  two other 
recently reported experiences[17,18] clearly show that, at 
least in some patients, the addition of  erlotinib to Gem 
has both biological and clinical activity: indeed, the most 
relevant finding reported herein is the strong predictive 
value of  the appearance of  skin rash. Patients develop-
ing erlotinib-related skin toxicity experience a more than 
doubled median OS (42 wk vs 15 wk, P = 0.03), and PFS 
(21 wk vs 10 wk, P = 0.001); conversely, the occurrence 
of  other toxicities, such as hematologic toxicity or diar-
rhea, has no impact on treatment activity and/or survival 
outcomes. A similar predictive effect had already been 
described in the registration trial of  erlotinib in PDAC, 
where patients experiencing grade 2 skin rash had a 
1-year survival of  43%[6] and is shared by other agents 
targeting the EGFR pathway, either small molecules or 
monoclonal antibodies, regardless of  the disease set-
ting[19-25]. The trial exploring the addition of  bevacizumab 
to Gem and erlotinib, also showed a significantly better 
outcome for patients developing skin rash, regardless 
of  the treatment arm[26]. A more recent randomized trial 
showed that skin rash is able to dichotomize patients re-
ceiving erlotinib between good and poor prognosis[27]. 
  In addition to skin rash, survival analysis of  the cur-
rent study also underlines the importance of  two other 
treatment-modified factors to guide the management of  
advanced PDAC patients: clinical benefit and decline in 
CA 19-9 levels. Though chosen as the primary end-point 
in the Gemcitabine registration trial by Burris et al[2], the 
relationship between CB and OS has never been vali-
dated. Interestingly, in the present trial the occurrence 
of  CB was a significant independent predictor of  longer 
OS, while objective response, as assessed by RECIST 
criteria, was not, a finding of  great clinical relevance in 
the context of  a disease with dismal prognosis, where 
symptom control represents a real issue for clinical prac-
tice. A reduction in CA 19-9 levels > 25% from baseline 
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could potentially benefit from Gem/erlotinib combinations. 
Peer review
This study investigated activity, toxicity, and prognostic factors for survival of 
erlotinib and FDR-Gem in advanced pancreatic cancer. They highlighted the 
correlation between the rash and efficacy. The similar studies were published 
in the past and they had the similar results, furthermore there were randomized 
controlled trials among them. This study is the confirmation of result of those 
studies, but it has reference to clinical practice. 
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